CMS pushes ahead with AMD (age-related macular degeneration) policy:
This article was originally published in Clinica
New US reimbursement policy for a procedure to treat the occult form of wet age-related macular degeneration (AMD) is proceeding, says the US Vitreous Society, an association specialising in retinal diseases. The society, which requested the change late last month, says the new policy is being implemented cautiously, as the drug in question, Visudyne (verteporfin), has not yet gained US approval for the indication (see Clinica No 981, p 11). The procedure involves using the drug in combination with a laser. The therapy has been designed by Novartis Ophthalmics (Atlanta, Georgia) and Canada's QLT (Vancouver). CLINICA -World Medical Device & Diagnostic News FILED 5 November 2001 COPYRIGHT 2001 PJB Publications Ltd
You may also be interested in...
The Environmental Working Group and Scientific Analytical Institute say inadequate testing of talc-containing personal-care products is to blame for findings of asbestos in cosmetics, including three of 21 powder-based cosmetics SAI analyzed at EWG’s request. They continue to push for updated testing standards that include electron microscopy as a core component.
Can Atlas Biomed unlock Japan's self-care market with its direct-to-consumer DNA and microbiome tests? HBW Insight catches up with the company's co-founder and CEO to discuss this and also how Atlas has been driving its European expansion plans despite coronavirus.
France's ANSES warns women using oral contraceptives not to use a supplement marketed by UK firm Hairburst after linking the product's consumption to two cases of severe acute hepatitis.